Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BTK inhibitors
Biotech
Sanofi's tolebrutinib fails 2 of 3 late-stage MS trials
Sanofi is still set on taking tolebrutinib to the FDA despite the BTK inhibitor falling short in two of three phase 3 trials that read out Monday.
James Waldron
Sep 2, 2024 1:00am
Sanofi nails phase 3 LUNA landing, sparking race to regulators
Apr 23, 2024 2:23am
Novartis lines up another potential indication for BTK inhibitor
Mar 9, 2024 12:00pm
Merck KGaA drops evobrutinib in wake of double phase 3 fail
Mar 7, 2024 9:54am
Sanofi BTK inhibitor readout in chronic hives sets up ph. 3 push
Feb 26, 2024 10:35am
Sanofi-backed Sudo seals $116M series B
Dec 20, 2023 8:30am